HCV research and anti-HCV drug discovery: toward the next generation.
HCV research and anti-HCV drug discovery: toward the next generation.
复制标题
DOI：
10.1016/j.addr.2007.08.021
复制
发表时间：
2007-10
影响因子：
16.1
通讯作者：
T. Wakita
中科院分区：
文献类型：
--
作者：
T. Wakita
丙型肝炎病毒（HCV）引起持续感染，导致慢性肝炎、肝硬化，最终导致肝细胞癌。目前HCV感染的治疗方法并不令人满意，需要更有效的抗病毒治疗。在这方面，由于缺乏适当的病毒培养系统和小动物感染模型，对HCV的详细分析受到阻碍。然而，最近在HCV研究方面取得了快速进展，例如亚基因组复制子系统、使用JFH-1克隆的病毒培养系统和移植有人肝细胞的Alb-uPA/SCID小鼠。这些进展将推动HCV研究和抗HCV药物的发现走向下一代。
Hepatitis C virus (HCV) causes persistent infection and induces chronic hepatitis, liver cirrhosis and finally hepatocellular carcinoma. Current therapies for HCV infection have not been satisfactory, and more effective anti-viral treatments are needed. In this regard, detailed analysis of HCV has been hampered by a lack of appropriate viral culture systems and small animal models of infection. However, rapid progress in HCV research has recently been achieved, such as a subgenomic replicon system, a viral culture system using JFH-1 clone and the Alb-uPA/SCID mouse transplanted with human liver cells. Such progress will propel HCV research and anti-HCV drug discovery toward the next generation.